Urology team joins major bladder cancer trial

Being a recognised high-quality service that sees a large number of patients, the Trust’s urology team has been successful in joining the prestigious iROC clinical trial. This is a phase III multi-centre, randomised controlled trial to compare the efficacy of robotically assisted radical cystectomy and intracorporeal urinary diversion with open radical cystectomy surgery in patients with bladder cancer. One of a few select sites in the NHS where the clinical trial will run, the team started its work this month (May 2018) – which is bladder cancer awareness month.

The urology team, which is based at the Lister, offers patients several state-of-the-art bladder cancer services – including blue-light bladder tumour resections and robotic bladder cancer surgery (including robotic urinary bladder reconstruction and diversion surgery).

Consultant urological surgeon, Mr Nikhil Vasdev, who is the principal investigator for the iROC study at the Lister and the Trust’s lead bladder cancer network surgeon, said:

“It is an absolute honour for our team to have been approached and now recognised as an iROC clinical trial site. We have recruited our first patient already – and within 48 hours of the trial commencing. We very much hope that the outcomes from this research will, in due course, be very important to helping services across the NHS and beyond to enhance the management of patients with bladder cancer undergoing both robotic and open surgery. I am very grateful to Prof John Kelly (UCLH) and Prof Jim Catto (Sheffield), who are the chief investigators for the iROC trial, in approving us as a trial site, as well as to Prof Philip Smith, our director of research here at the Trust, for supporting our application.”​